Authors:
Yanchen Wang, Elysia K. Donovan, Mark N. Levine, Timothy Joseph Whelan, Anand Swaminath, Sameer Parpia, Anand Swaminath, Gordon S. Okawara, Ranjan Kumar Sur, Jim Wright, Marcin Wierzbicki, Timothy E. Owen
+88 more
A. Ashworth, Conrad B Falkson, Aamer Mahmud, Sou Thain, Theodoros K. Tsakiridis, Gordon S. Okawara, Ranjini Tolakanahalli, Brian Yaremko, Alexander Louie, David Anthony Palma, George Rodrigues, Edward Yu, Stewart Gaede, Kevin Ramchandar, Margaret Anthes, Rita Murphy, Khalid Hirmiz, Ming Pan, Junaid Yousuf, John Agapito, Elaine S. Wai, Tanya S. Berrang, Paul Blood, Jean‐Marc Bourque, Juliana Caon, Saibishkumar Parameswaran, Sally Smith, Susan Tyler, Parminder Basran, Naseer Ahmed, Bashir Bashir, Amitava Chowdhury, Arbind Dubey, Julian Kim, Ahmet Leylek, Sankar Venkataraman, Harold Lau, Steve J. Angyalfi, Elizabeth Kurien, Gerald Lim, Nicolas Paul Ploquin, Zsolt Gabos, Brock John Debenham, Alysa M. Fairchild, Tirath Nijjar, Wilson Roa, Diane Marie Severin, Don Yee, Heather Warkentin, Robert Thompson, Amanda Caissie, Holly Campbell, Elisa Chan, Farah Naz, Jon Dysart, Edward Lawrence, Sérgio de Faria, Bassam Abdulkarim, Marie Duclos, Neil Kopek, Russell Ruo, Alexis Bujold, Christian Boukaram, Pierre Chabot, Bernard Fortin, Benoît Laliberté, David Nguyen, Alma Sylvestre, Dominique Martin, Édith Filion, Houda Bahig, Marie‐Pierre Campeau, Toni Vu, Dominic Béliveau‐Nadeau, Nelson Leong, Asim Amjad, Gillian Bailey, Michelle Ferguson, Joshua Giambattista, Elaine Liu, Shazia Mahmood, Dilip Panjwani, Evgeny Sadikov, Derek Suderman, Patricia Tai, Varun-Singh Thakur, Vijayananda Kundapur, Bryan Brunet
Cited by:
0
References:
21
Abstract
Introduction : The results of the LUSTRE trial investigating stereotactic body radiotherapy in early-stage non-small cell lung cancer were inconclusive. A Bayesian analysis could potentially address this by integrating prior knowledge. Methods : The LUSTRE trial was a randomized-controlled superiority trial conducted from 2014 to 2020. Patients with medically inoperable Stage 1 non-small cell lung cancer were randomized 2:1 to stereotactic radiotherapy (intervention) or conventional radiotherapy (control). The primary outcome was time-to-local control, defined as the period from randomization to absence of a primary tumor or marginal failure during follow-up. Primary analyses used Bayesian multivariable Cox regression, adjusting for strata (tumor size, tumor location, and clinical center). A neutral prior distribution was used for primary analysis, with optimistic (obtained from meta-analyses of two previous trials) and pessimistic prior distributions/knowledge for sensitivity analyses. Results : Among 233 patients, 154 received stereotactic radiotherapy, and 79 received conventional radiotherapy. Using a non-informative neutral prior distribution, there was a 91% probability that the posterior adjusted hazard ratio (aHR) for local control with stereotactic radiotherapy was less than 1 (posterior aHR: 0.63, 95% credible interval: 0.32, 1.25). Incorporating the optimistic prior distribution, the posterior aHR was 0.62 (95% credible interval: 0.37, 1.02), indicating a 97% probability of benefit. Under the pessimistic prior distribution, the posterior aHR was 0.97 (95% credible interval: 0.71, 1.34), suggesting a 57% probability of benefit. Conclusions : Post-hoc Bayesian re-analyses provided additional insight into the posterior probability of local control benefit with stereotactic radiotherapy. MicroAbstract A post-hoc Bayesian re-analysis of the inconclusive LUSTRE trial examined stereotactic body radiotherapy versus conventional radiotherapy in 233 patients with medically inoperable Stage 1 non-small cell lung cancer. Using non-informative priors, there was a 91% probability that stereotactic radiotherapy improved local control (posterior adjusted hazard ratio: 0.63, 95% credible interval: 0.32–1.25), providing additional probabilistic insight beyond the original frequentist analysis. LUSTRE trial registry ID NCT01968941 (date of registration: Oct.21, 2013)